Fellowship · New Hyde Park, NY
Sponsored by Zucker School of Medicine at Hofstra/Northwell
Exagamglogene Autotemcel for Severe Sickle Cell Disease.
The New England journal of medicine · 2024 · 351 citations · Lyndsay Molinari
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.
The New England journal of medicine · 2024 · 205 citations · Andrew Doan
Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.
The New England journal of medicine · 2022 · 352 citations · Stacey Rifkin-Zenenberg, Banu Aygun
Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.
The New England journal of medicine · 2021 · 288 citations · Diana Osorio
Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C.
Blood · 2021 · 155 citations · Stacey Rifkin-Zenenberg
Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease.
The New England journal of medicine · 2026 · 16 citations · Stacey Rifkin-Zenenberg
Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial.
Blood · 2025 · 26 citations · Suchitra Acharya
Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 58 citations · Derek Hanson